Hami's Oraxol, novel oral formulation of paclitaxel, inhibits neointimal hyperplasia in rat model

Hanmi Pharm said recently that Oraxol, oral formulations of paclitaxol, provide an effective means of inhibiting proliferative response to vascular injury in rat treated at a lower dose (5mg/kg), according to the recent animal experiments.

In the study, which was jointly conducted by a research team of Dr. Kim Dong-woon, College of Medicine, Chungbuk National University, Hanmi noted that the...